Last edition
News about "intravenous pembrolizumab"
FDA Approves Diagnostic Tool for Pembrolizumab Combo in Endometrial Cancer
The US FDA has cleared the OncoMate MSI Dx Analysis System as a companion diagnostic to guide pembrolizumab-based combination therapy in advanced endometrial cancer. The PCR-based assay determines microsatellite instability (MSI) status in tumour tissue, with support from Merck, developer of pembrolizumab and lenvatinib.
Intravenous Pembrolizumab | 15/11/2025 | By Dineshwori
FDA Approves Subcutaneous Version of Keytruda for Solid Tumours
The U.S. Food and Drug Administration (FDA) has granted approval for a new subcutaneous formulation of Merck’s cancer immunotherapy Keytruda, now marketed as Keytruda Qlex.<br />
Intravenous Pembrolizumab | 22/09/2025 | By Darshana
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy